Summary. Glycosylation of low density lipoproteins obtained from 16 patients with Type 1 (insulin-dependent) diabetes and from 16age-, sex-, and race-matched controls, was determined. The diabetic patients were normolipaemic and were in good or fair glycaemic control. Eleven patients performed home blood glucose monitoring. Glycosylation of low density lipoproteins in the diabetic patients was significantly higher (p < 0.001) than in the control subjects, and was significantly correlated with haemoglobin Ale, (p < 0.01), glycosylation of plasma proteins, (p < 0.001), and mean home blood glucose, (p < 0.01). This study confirms that, in diabetic patients, increased glycosylation of low density lipoprotein occurs to an extent which correlates closely with other commonly used indices of glycaemic control.
Increased non-enzymatic glycosylation [1] has been demonstrated in many circulating and tissue proteins in diabetes [2] . Since lipoproteins are intimately involved with the development of atherosclerosis, the major cause of morbidity and mortality in diabetic patients [3] , any modification of lipoprotein particles occuring in the diabetic state is of considerable interest. Studies using low density lipoprotein (LDL) glycosylated in vitro have demonstrated that the modified lipoprotein is degraded less rapidly than control LDL by human fibroblasts grown in tissue culture [4, 5] . This may explain the increased levels of circulating LDL usually found in poorly controlled diabetic patients. However, the conditions of in vitro glycosylation used in these studies were likely to result in much higher levels of glycosylation than those occuring in vivo. Although a similar effect on LDL degradation by fibroblasts was also observed when lesser degrees of in vitro glycosylation were studied [6] , the clinical significance of these findings is unclear because the extent of glycosylation occuring in vivo in typical diabetic patients has not been investigated in detail. In this study, we have compared the degree of glycosylation of LDL from a group of Type 1 (insulindependent) diabetic patients, in good or fair glycaemic control, with that of LDL from a matched non-diabetic control group. We have related LDL glycosylation to other parameters of recent glycaemic control -haemoglobin Alc, glycosylation of plasma proteins and the results of home blood glucose monitoring.
Subjects and methods
Sixteen patients were recruited from the Private Diagnostic Clinic of the Medical University of South Carolina. All had Type 1 diabetes mellitus diagnosed according to the criteria established by the National Diabetes Data Group [7] . For every diabetic patient, an age-, sex-, and race-matched non-diabetic control was recruited from the staff at the Medical University of South Carolina, and blood was drawn on the same day from each member of the matched pair. One patient/ control pair was studied on two separate occasions when the diabetic member was in good and poor glycaemic control (HbAlc 6.3 and 10.1% respectively). Of the 16 diabetic patients, 11 performed home blood glucose monitoring, and were asked to provide measurements of blood glucose taken four times daily (before meals) during the week prior to blood sampling. Seven patients had evidence of background retinopathy and three had evidence of neuropathy. Three patients and one control were receiving thyroxine therapy for hypothyroidism but were clinically euthyroid, one patient and two controls were taking diuretics (furosemide or thiazide) and one control a flblocking agent. One diabetic patient and her corresponding control were in the third trimester of pregnancy. Additional characteristics of the diabetic and control groups, including weight, age, sex, and racial distribution are shown in Table 1 .
A 60-ml sample of venous blood was collected from all subjects after a 12-14h fast and before the morning insulin dose to isolate LDL and to measure plasma glucose, HbAlo, plasma lipid and lipoprotein levels.
Informed consent, as approved by the Institutional Review Board of the Medical University of South Carolina, was obtained from all subjects involved in the study.
LDL isolation
LDL (1.019 < d < 1.063 g/ml) was isolated from plasma at 15 °C by sequential ultracentrifugation [8] in a Beckman 50 Ti rotor (Beckman In- 
Plasma proteins
For each subject two millilitres of fresh plasma containing 0.01% EDTA was stored at -70 °C for later determination of glycosylation.
Measurement of glycosylation of LDL and plasma proteins
Glycosylation of LDL and plasma proteins was determined by affinity chromatography, using a method similar to that employed by Yue et al. [10] in the measurement of tissue protein glycosylation. Stored LDL samples were thawed and aggregated lipoproteins were dispersed by brief (< 5 s) sonication (probe-sonicator, Heat SystemsUltrasonic Inc, Plainview, NY, USA). Stored plasma samples were thawed and 1 ml of each was diluted by adding 4 ml of 0.9% (w/v) NaC1 solution containing 0.01% (w/v) EDTA. One millilitre of the diluted plasma was dialysed overnight at 4 °C against a large excess ~ of saline/EDTA to remove free glucose, and its protein concentration was determined by the Lowry method [9] . A 200 ~tl aliquot of the LDL sample (200 ~tg protein) or a 14-gl aliquot of the plasma protein sample (approximately 200 ~tg protein) made up to 200 p3 with saline/ EDTA, was added to 250 p.1 sodium carbonate buffer (0.2 M Na2CO3, adjusted to pH 9.0) and 50 p3 1% sodium dodecyl sulfate (SDS) in a teflon-lined screw-topped test tube. Ketoamine-linked glucose adducts were reduced and radio-labeled by addition of 20 ixl of tritiated sodium borohydride (5 mCi/ml, 360 mCi/mmol, New England Nuclear, Boston, Mass, USA) followed by incubation for 1 h on ice and 3 h at room temperature. It was determined that these conditions produced maximal incorporation of tritium in the glycosylated protein, and that tritium incorporation was linearly related to the amount of protein present when up to 400 lxg protein were used. Excess tritium was discharged by the addition of an equal volume (520 p.1) of 12 N hydrochloric acid, and acid hydrolysis was carried out for 18 h at 95 °C [11] . To minimize losses and experimental error, the reduction and hydrolysis procedures were performed in the same test tube. The samples were dried using a rotary evaporator and residual acid was removed by re-dissolving the residue in 200 Ixl of distilled water, drying again, and finally dissolving in 500 gl distilled water. A 350 ~xl aliquot was added to 35;0 lxl of HEPES buffer (100 mmol/l HEPES, 20 mmol/1 MgCI2, pH 8.5) and applied to an affinity column. Disposable polystyrene columns (8 × 120mm, Pierce Chemical Company, Rockford, Ill, USA) containing 2 ml of m-aminophenyl boronic acid affinity resin (Matrex Gel PBA-60, Amicon Corp., Danvers, Mass, USA) were used, and were equilibrated at pH 8.5 with 50 mmol/1 HEPES/10 mmol/1 MgC12 buffer, as recommended by the manufacturer. After application of the sample, the column was washed with five column volumes of HEPES buffer, after which radioactivity in the eluate was less than three times background. Hexitol-amino-acid was eluted using three 2 ml aliquots of 0.1 mol/1 acetic acid. Tritium radioactivity in these washes was counted to estimate the relative content of hexitol-amino-acid in the various samples.
To quantitate the amount of hydrolysed apolipoprotein or plasma protein applied to the affinity column, the free amino-group content of each hydrolysate was measured, in triplicate, by the trinitrobenzenesulfonic acid (TNBS) method [12, 13] . The assay was standardised using a known quantity of LDL, hydrolysed under identical conditions, and the result expressed as gg of hydrolysed protein.
The extent of glycosylation of LDL or plasma protein was expressed as counts per rain. 3H-hexitol-amino-acid radioactivity per lxg hydrolysed protein. The results reported here were obtained from five separate experiments conducted over a 2 week period. In every case both members of a diabetic-control pair were studied in the same experiment, and the same batch of tritiated sodium borohydride was used throughout. The between-assay coefficient of variation for the whole procedure was 10.8% (n =6); and the within-assay variation was 7.8% for LDL and 7.1% for plasma proteins.
Other methods
Home blood glucose measurements were obtained and recorded by the patients using Dextrostix and a Glucometer (Ames Division, Miles Laboratories Inc., Elkhart, Ind, USA). Plasma glucose was assayed using the glucose oxidase method, as adapted for use in the Beckman glucose analyser [14] . HbAlo was measured by isoelectric focusing of erythrocyte hemolysates in a gradient of pH 6-8 [15] .
Plasma total cholesterol and total triglyceride were measured by the semi-automated methods standardised by the Lipid Research Clinics Program [16] . The cholesterol content of LDL and VLDL was obtained using the above methodology after separation of the lipoproteins by ultracentrifugation as previously described [17] . HDL cholesterol was measured in whole plasma after precipitation of VLDL and LDL with sodium phosphotungstate/magnesium chloride as previously described [18] .
Statistical analysis
Statistical analysis was performed using the paired Student's t-test to compare differences between paired data. Correlation coefficients were determined by linear regression analysis [19] . All results are expressed as mean_+ SEM.
Results
A significant correlation was found between LDL glycosylation and plasma protein glycosylation (p < 0.001, Fig. 1 ). The 11 patients who performed home blood glu- Fig. 2) . Similarly, LDL glycosylation and plasma protein were significantly correlated with HbAle (p < 0.01 and p < 0.001 respectively, Fig. 3 ). Glycosylation of LDL and of plasma proteins was significantly higher in diabetic patients than in control subjects (p < 0.001, Table 2 ). As expected, fasting plasma glucose and HbA1o levels were significantly higher in diabetic patients than in control subjects ( Table 2) . The values indicate that the majority of patients was in good or fair glycaemic control.
Plasma lipid levels in the diabetic and control groups are shown in Table 3 . There were no significant differences between the two groups in total triglycerides, total cholesterol or in the cholesterol content of LDL, VLDL or HDL.
Discussion
Our study demonstrates increased glycosylation of LDL in a group of normolipaemic Type I diabetic patients in good to fair glycaemic control. The findings are consistent with those of Schleicher et al. [20] , and Witztum et al. [5] , who found similar increases in glycosylation of LDL in diabetes but did not provide details of lipid levels or glycaemic control in the patients they studied. In contrast, Curtiss and Witztum [21] , using an immunochemical method, found a much greater increase in apo-B glycation in three severely hyperglycaemic, hyperlipidaemic diabetic patients. LDL glycation in our diabetic patients was increased 1.6-fold over control values, a similar increase to that found for haemoglobin (1.5-fold) and plasma proteins (2.2-fold). However, we observed that, in both diabetic patients and control subjects, LDL glycosylation was lower than plasma protein glycosylation (Table 2 ). This may be partly because LDL apolipoprotein has a shorter circulating half-life (approximately 3 days [22] ) than the majority of plasma proteins (albumin, 17-23 days; g-globulin, 15-26 days [23] ). The apolipoprotein component, being partially embedded in the lipoprotein particle, may also be less accessible than other proteins to free glucose. We found significant correlations between LDL glycosylation and three other parameters of glycaemic control -glycosylation of plasma proteins, mean home blood glucose concentration, and haemoglobin Ale. Glycosylation of LDL was more closely correlated with plasma protein glycosylation and with mean home blood glucose than with haemoglobin Ale, possibly because the latter reflects glycaemic control over a longer period of time. We used boronate affinity chromatography to measure LDL glycosylation. This method has the advantage of being highly specific; only compounds with co-planar cis-hydroxyl groups will form stable complexes with the boronate gel under alkaline conditions. Of the compounds resulting from the reduction and hydrolysis of LDL, only glycosylated amino acids contain this structural conformation. The method has the additional advantage, particularly important in work with lipoproteins, of requiring only small quantities of protein. We must emphasize the importance of thorough removal of glucose from the LDL samples prior to the assay, since glucitol binds effectively to the boronate gel and therefore can cause interference. Furthermore, we recommend that freezing of LDL samples should be avoided if possible -in this study sonication was necessary to disperse agglutinated lipoprotein after thawing.
The hypothesis that an increase in LDL glycosylation, to the extent occuring in diabetic patients in good or fair glycaemic control, may be important in the pathogenesis of atherosclerosis is supported by recent studies in our laboratory. We have shown that LDL glycosylated in vitro increases cholesteryl ester (CE) synthesis and CE accumulation in human macrophages [24] . Macrophages are thought to be the main precursors of foam ceils which are characteristic of the early atheromatous plaque. We have also demonstrated increased CE synthesis in macrophages exposed to LDL isolated from a small group of normolipaemic diabetic patients, and found a significant correlation between CE synthesis and LDL glycosylation [25] . These findings may help to explain why the diabetes, irrespective of type [26, 27] , is an independent risk factor in the development of atherosclerosis. They may also have relevance to the observation that lesser degrees of hyperglycaemia may be associated with an increased risk of vascular disease [28, 29] .
In conclusion, our study demonstrates the presence of increased glycosylation of LDL in a group of relatively well-controlled Type 1 diabetic patients, and it is possible that this increase may accelerate the development of atherosclerosis. The extent of LDL glycosylation correlates well with commonly used indices of glycaemic control and our findings, therefore, provide further evidence that optimal glycaemic control is an important goal in the management of all diabetic patients.
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